Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.

doi:10.1007/s00520-020-05320-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer - 1 May 2020

Lorusso Domenica, Bologna Alessandra, Cecere Sabrina Chiara, De Matteis Elisabetta, Scandurra Giusy, Zamagni Claudio, Arcangeli Valentina, Artioli Fabrizio, Bella Mariangela, Blanco Giusi, Cardalesi Cinzia, Casartelli Clelia, De Vivo Rocco, Di Napoli Marilena, Gisone Emanuele Baldo, Lauria Rossella, Lissoni Alberto Andrea, Loizzi Vera, Maccaroni Elena, Mangili Giorgia, Marchetti Claudia, Martella Francesca, Naglieri Emanuele, Parolin Veronica, Ricciardi Giusy, Ronzino Graziana, Salutari Vanda, Scarfone Giovanna, Secondino Simona, Spagnoletti Ilaria, Tasca Giulia, Tognon Germana, Guarneri Valentina

Abstract excerpt

Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved as maintenance therapy of recurrent ovarian cancer (OC) patients with a BRCA mutation. To achieve the maximum clinical benefit, adherence to olaparib must be persistent. However, in clinical practice, this is challenged by the frequent suboptimal management of toxicities. In view of the expanding use of olaparib also in Italy, physicians must...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anemia

Share to BRCA2 Protein

Share to Fatigue

Share to Nausea

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Vomiting

Source

Open in PubMed

Identifiers

PMID: 32048043
DOI: 10.1007/s00520-020-05320-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.PMID 32048043Read ↗

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.Semantic proximity Read ↗

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.Semantic proximity Read ↗

Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World DataSemantic proximity Read ↗

Experiencia con el uso de olaparib en pacientes con cáncer de ovario.Semantic proximity Read ↗

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.Semantic proximity Read ↗

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.Semantic proximity Read ↗

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.Semantic proximity Read ↗

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.Semantic proximity Read ↗

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.Semantic proximity Read ↗

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.Semantic proximity Read ↗

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.